COO

Business Context and Reporting Period

Company: The Cooper Companies, Inc. (COO)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended October 31, 2025
Business Overview: A global medical device company operating through two segments: CooperVision (contact lenses and myopia management) and CooperSurgical (fertility and women's health products and services). The company serves over 130 countries with a workforce of more than 15,000 employees.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Consolidated net sales increased 5% to $4.09 billion, driven by growth in both segments. CooperVision sales rose 5% to $2.74 billion, while CooperSurgical sales increased 5% to $1.35 billion.
• Profitability Decline: Operating income decreased 3% to $682.9 million. This was primarily due to a significant decline in CooperSurgical operating income (down 63% to $43.4 million) caused by inventory and long-lived asset write-offs, severance costs from workforce optimization, and increased amortization.
• Margin Compression: Consolidated gross margin decreased from 67% to 66% due to the aforementioned write-offs and severance costs.
• Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 6% to $1.63 billion, and R&D expenses increased 11% to $172.2 million, reflecting increased project spend and workforce optimization costs.
• Interest Expense: Decreased 13% to $100.0 million due to lower interest rates and lower average debt balances.

Guidance, Outlook, and Risks

Management Outlook: Management remains optimistic about long-term prospects in the contact lens and healthcare markets. CooperVision is focusing on market penetration of single-use silicone hydrogel lenses and myopia management products (MiSight). CooperSurgical is expanding its integrated solutions model in fertility and women's health.

Capital Allocation:

• Share Repurchases: In September 2025, the Board increased the repurchase authorization to $2.0 billion. As of October 31, 2025, $966.4 million remained available. The company repurchased 4.1 million shares for $290.1 million in fiscal 2025.
• Dividends: The semiannual dividend was discontinued in December 2023; no dividends were paid in fiscal 2025.

Key Risks and Contingencies:

• Regulatory Environment: Significant exposure to FDA, EU MDR/IVDR, and UK MHRA regulations. Changes in reimbursement policies and healthcare reform (e.g., Inflation Reduction Act, One Big Beautiful Bill Act) pose pricing pressures.
• Internal Controls: A material weakness in IT general controls for CooperSurgical U.S. operations identified in fiscal 2024 was remediated as of October 31, 2025.
• Supply Chain & Geopolitics: Risks related to raw material shortages (specifically silicone hydrogel components), international conflicts, tariffs, and foreign currency fluctuations.
• Cybersecurity: Ongoing threats to IT systems and data security, though no material incidents were reported in the period.

Investor Verification Checklist

• CooperSurgical Profitability: Verify the sustainability of CooperSurgical's operating margin recovery following the 63% drop in operating income driven by one-time write-offs and severance.
• Debt Covenants: Confirm continued compliance with Total Leverage and Interest Coverage ratios under the 2024 Credit Agreement and 2021 Term Loan.
• Regulatory Approvals: Monitor the status of MiSight 1 day lens approvals in key markets (Japan approval noted in August 2025) and compliance with EU MDR/IVDR transition deadlines.
• Internal Control Remediation: Review future filings to ensure the remediation of the IT general control weakness remains effective and no new material weaknesses arise.
• Share Repurchase Execution: Track the utilization of the remaining $966.4 million repurchase authorization and its impact on earnings per share.